Burkhart Erin
- SEC CIK
- 0001927648
No open-market purchases or sales filed in the past year.
Current role at each company
- GILD Gilead Sciences, Inc.SVP, Controllershipas of Sep 23, 2026
- BMRN Biomarin Pharmaceutical IncGVP, Chief Accounting Officeras of May 20, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Burkhart Erin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BMRN Biomarin Pharmaceutical Inc
GVP, Chief Accounting Officer5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2025 (view filing) | May 20 | Same day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.79K | $59.31 | −$105.9K | −11.2%14.2K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 19 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.29K | $71.52 | −$92.6K | −7.1%17.0K after | 10b5-1 |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.34K | $68.38 | −$91.9K | −9.3%13.1K after | 10b5-1 |
| Aug 15, 2024 (view filing) | Aug 13 | 2 days | Burkhart ErinGVP, Chief Accounting Officer | SSale | −714 | $90.00 | −$64.3K | −4.7%14.4K after | 10b5-1 |
| Apr 12, 2024 (view filing) | Apr 10 | 2 days | Burkhart ErinGVP, Chief Accounting Officer | SSale | −2.29K | $90.00 | −$205.7K | −12.4%16.2K after | 10b5-1 |